influenza
respiratori
viral
pathogen
associ
signific
morbid
mortal
global
infect
rang
rel
mild
present
eg
cough
sore
throat
sever
lower
respiratori
tract
infect
eg
pneumonia
sever
case
may
associ
hospit
intens
care
admiss
death
young
children
elderli
individu
chronic
condit
highest
risk
sever
individu
multipl
laboratori
test
cours
ill
therefor
first
posit
influenza
test
influenza
season
use
potenti
control
sampl
select
among
test
neg
influenza
influenza
season
use
first
neg
test
case
control
test
day
vaccin
exclud
analysi
influenza
vaccin
statu
determin
influenza
vaccin
registri
registri
combin
data
four
databas
record
influenza
vaccin
event
see
follow
administr
data
set
use
studi
alberta
health
immun
advers
reaction
immun
system
immari
contain
individu
consid
inpati
least
one
physician
claim
inpati
servic
day
specimen
collect
specimen
collect
occur
inpati
stay
other
consid
outpati
individu
immunocompromis
condit
defin
determin
physician
claim
macar
organ
transplant
determin
use
macar
immunocompromis
drug
dispens
identifi
pin
use
multivari
logist
regress
estim
influenza
vaccin
effect
adjust
x
estim
separ
influenza
season
influenza
subtyp
ie
influenza
b
covari
consid
adjust
model
sa
version
use
statist
analysi
sa
institut
inc
cari
nc
estim
compar
shed
influenza
viru
continu
approxim
day
symptom
onset
bia
result
specimen
collect
long
symptom
onset
use
studi
use
threshold
day
test
robust
find
sensit
analysi
perform
control
restrict
specimen
posit
differ
respiratori
viru
ie
coronaviru
human
respiratori
syncyti
viru
suggest
sullivan
et
al
potenti
limit
studi
sampl
util
clinic
isol
taken
cours
normal
patient
care
standard
case
definit
util
studi
test
robust
find
analysi
repeat
use
case
control
given
diagnosi
code
acut
respiratori
infect
day
specimen
collect
per
sese
databas
macar
appendix
list
code
use
defin
acut
respiratori
infect
protocol
describ
estim
season
influenza
use
specimen
collect
routin
influenza
diagnost
well
administr
data
vaccin
record
key
strength
approach
larg
sampl
size
approach
allow
calcul
near
realtim
precis
influenza
estim
week
prior
influenza
season
peak
creat
earli
warn
system
public
health
season
vaccin
found
exceedingli
low
effect
earli
notif
assist
public
health
determin
polici
messag
alloc
resourc
antivir
agent
staf
emerg
depart
counter
potenti
sever
influenza
season
larg
sampl
size
also
allow
stratifi
analys
base
product
age
group
region
reduc
nondifferenti
misclassif
would
bia
odd
ratio
toward
null
thu
underestim
final
certain
captur
result
respiratori
viru
test
provinc
respiratori
viru
test
central
provlab
limit
use
pointofcar
test
limit
methodolog
compar
tradit
method
estim
use
sentinel
physician
network
standard
clinic
case
definit
appli
determin
studi
elig
sensit
analysi
restrict
healthcar
encount
diagnosi
code
acut
respiratori
infect
use
proxi
standard
case
definit
inclus
confound
import
estim
adjust
known
confound
measur
use
administr
data
frailti
demonstr
potenti
confound
tab
carmustin
iv
pw
carmustin
top
sol
avl
chlorambucil
tab
cyclophosphamid
inj
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
estramustin
disodium
phosphat
cap
estramustin
phosphat
cap
lomustin
cap
lomustin
cap
lomustin
cap
mechlorethamin
iv
pw
melphalan
tab
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
f
r
p
e
e
r
r
e
v
e
w
n
l
din
drug
name
rout
administr
strength
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
capsul
thiotepa
inj
pw
capecitabin
fc
tab
capecitabin
fc
tab
capecitabin
fc
tab
capecitabin
fc
tab
capecitabin
tab
capecitabin
tab
capecitabin
tab
capecitabin
tab
cladribin
iv
sol
cytarabin
inj
pw
cytarabin
inj
pw
cytarabin
inj
pw
cytarabin
iv
pw
cytarabin
iv
pw
fludarabin
phosphat
tab
fluorouracil
iv
sol
fluorouracil
top
crm
hydroxyurea
cap
hydroxyurea
cap
hydroxyurea
cap
mercaptopurin
tab
mercaptopurin
tablet
methotrex
inj
tab
dasatinib
tab
dasatinib
tab
dasatinib
tab
erlotinib
hcl
tab
erlotinib
hcl
tab
erlotinib
hcl
tab
erlotinib
hcl
tablet
erlotinib
hcl
tablet
ibrutinib
cap
imatinib
mesyl
tab
ruxolitinib
tab
ruxolitinib
tab
ruxolitinib
tab
trametinib
recombin
tab
asparaginas
inj
pw
axitinib
tab
axitinib
tab
fc
bortezomib
iv
pw
dacarbazin
iv
pw
dacarbazin
iv
pw
gefitinib
tab
imatinib
mesyl
cap
imatinib
mesyl
fc
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
f
r
p
e
e
r
r
e
v
e
w
n
l
din
drug
name
rout
administr
strength
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
lapatinib
ditosyl
tab
nilotinib
cap
nilotinib
cap
pazopanib
hcl
tab
isol
consid
elig
inclus
analysi
met
follow
criteria
valid
phn
record
isol
resid
longterm
care
facil
isol
collect
least
four
week
initi
public
influenza
vaccin
program
isol
collect
influenza
season
determin
use
method
recommend
r
import
ensur
popul
chanc
expos
influenza
suffici
influenza
test
influenza
season
use
potenti
control
sampl
select
among
test
neg
influenza
influenza
season
use
first
neg
test
case
control
test
day
vaccin
exclud
analysi
influenza
vaccin
statu
determin
influenza
vaccin
registri
registri
combin
data
four
databas
record
influenza
vaccin
event
see
follow
administr
data
set
use
studi
alberta
health
immun
advers
reaction
immun
system
immari
contain
qualiti
administr
dataset
alberta
extens
review
individu
consid
inpati
least
one
physician
claim
inpati
servic
day
specimen
collect
specimen
collect
occur
inpati
stay
other
potenti
limit
studi
sampl
util
clinic
isol
taken
cours
normal
patient
care
standard
case
definit
util
studi
test
robust
find
analysi
repeat
use
case
control
protocol
describ
estim
season
influenza
use
specimen
collect
routin
influenza
diagnost
well
administr
data
vaccin
record
key
strength
approach
larg
sampl
size
approach
allow
calcul
near
realtim
precis
influenza
estim
week
prior
influenza
season
peak
creat
earli
warn
system
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
estramustin
disodium
phosphat
cap
estramustin
phosphat
cap
lomustin
cap
lomustin
cap
lomustin
cap
mechlorethamin
iv
pw
melphalan
tab
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
tablet
erlotinib
hcl
tablet
ibrutinib
cap
imatinib
mesyl
tab
ruxolitinib
tab
ruxolitinib
tab
ruxolitinib
tab
trametinib
recombin
tab
asparaginas
inj
pw
axitinib
tab
axitinib
tab
fc
bortezomib
iv
pw
dacarbazin
iv
pw
dacarbazin
iv
pw
gefitinib
tab
imatinib
mesyl
cap
imatinib
mesyl
fc
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
season
potenti
control
defin
base
individu
first
neg
influenza
test
season
one
control
case
randomli
select
base
week
specimen
collect
estim
vaccin
effect
use
multivari
logist
regress
import
ensur
popul
chanc
expos
influenza
suffici
influenza
test
influenza
season
use
potenti
control
sampl
select
among
test
neg
influenza
influenza
season
use
first
neg
test
case
control
test
day
vaccin
exclud
analysi
influenza
vaccin
statu
determin
influenza
vaccin
registri
registri
combin
data
four
databas
record
influenza
vaccin
event
see
follow
administr
data
set
use
studi
shall
appli
andor
iii
accord
term
applic
us
feder
govern
offic
employe
act
part
offici
duti
worldwid
perpetu
irrevoc
royaltyfre
basi
bmj
publish
group
ltd
bmj
license
relev
journal
coown
bmj
coowner
journal
publish
work
bmj
open
bmj
product
f
r
p
e
e
r
r
e
v
e
w
n
l
exploit
right
set
licenc
submit
author
accept
understand
suppli
made
term
made
bmj
submit
author
unless
act
employe
behalf
employ
postgradu
student
affili
institut
pay
applic
articl
publish
charg
apc
open
access
articl
submit
author
wish
make
work
avail
open
access
basi
intend
pay
relev
apc
term
reus
open
access
shall
govern
creativ
common
licenc
detail
licenc
creativ
common
licenc
appli
work
set
licenc
refer
tab
cyclophosphamid
inj
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
iv
pw
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
cyclophosphamid
tab
estramustin
disodium
phosphat
cap
estramustin
phosphat
cap
lomustin
cap
lomustin
cap
lomustin
cap
mechlorethamin
iv
pw
melphalan
tab
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
temozolomid
cap
tablet
erlotinib
hcl
tablet
ibrutinib
cap
imatinib
mesyl
tab
ruxolitinib
tab
ruxolitinib
tab
ruxolitinib
tab
trametinib
recombin
tab
asparaginas
inj
pw
axitinib
tab
axitinib
tab
fc
bortezomib
iv
pw
dacarbazin
iv
pw
dacarbazin
iv
pw
gefitinib
tab
imatinib
mesyl
cap
imatinib
mesyl
fc
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
imatinib
mesyl
tab
import
ensur
popul
chanc
expos
influenza
suffici
influenza
test
influenza
season
use
potenti
control
sampl
select
among
test
neg
influenza
influenza
season
use
first
neg
test
case
control
test
day
vaccin
exclud
analysi
influenza
vaccin
statu
determin
influenza
vaccin
registri
registri
combin
data
four
databas
record
influenza
vaccin
event
see
follow
administr
data
set
use
studi
f
r
p
e
e
r
r
e
v
e
w
n
l
consid
outpati
individu
immunocompromis
condit
defin
diagnosi
hiv
receiv
organ
transplant
receiv
oral
corticosteroid
day
antineoplast
agent
anoth
immunocompromis
drug
commun
pharmacist
past
month
appendix
hiv
diagnosi
ari
determin
physician
claim
macar
organ
transplant
determin
use
macar
immunocompromis
drug
dispens
identifi
pin
vaccin
effect
data
refresh
analysi
complet
everi
two
week
peak
protocol
describ
estim
season
influenza
use
specimen
collect
routin
influenza
diagnost
well
administr
data
vaccin
record
key
strength
approach
larg
sampl
size
approach
allow
calcul
time
precis
influenza
estim
week
prior
influenza
season
peak
creat
earli
warn
system
public
author
would
like
acknowledg
staff
alberta
health
servic
provlab
assist
provid
administr
laboratori
data
sourc
could
implement
protocol
licenc
shall
appli
andor
iii
accord
term
applic
us
feder
govern
offic
employe
act
part
offici
duti
worldwid
perpetu
irrevoc
royaltyfre
basi
bmj
publish
group
ltd
bmj
license
relev
journal
coown
bmj
coowner
journal
publish
work
bmj
open
bmj
product
exploit
right
set
licenc
submit
author
accept
understand
suppli
made
term
made
bmj
submit
author
unless
act
employe
behalf
employ
postgradu
student
affili
institut
pay
applic
articl
publish
charg
apc
open
access
articl
submit
author
wish
make
work
avail
open
access
basi
intend
pay
relev
apc
term
reus
open
access
shall
govern
creativ
common
licenc
detail
licenc
creativ
common
licenc
appli
work
set
licenc
refer
f
r
p
e
e
r
r
e
v
e
w
n
l
f
r
p
e
e
r
r
e
v
e
w
n
l
